Management of Helicobacter pylori infections

Amin Talebi Bezmin Abadi1 and Johannes G. Kusters2*

Abstract

Background: Infection with Helicobacter pylori is associated with severe digestive diseases including chronic gastritis, peptic ulcer disease, and gastric cancer. Successful eradication of this common gastric pathogen in individual patients is known to prevent the occurrence of peptic ulcer disease and gastric cancer.

Discussion: With half of the world’s population being infected with H. pylori and only few antibiotics result in an effective eradication, a successful antibiotic driven worldwide eradication program seems unlikely. In addition, H. pylori eradication is not always beneficial as it has been described that eradication can be associated with an increased frequency of other disorders such as pediatric asthma, inflammatory bowel diseases and Barrett’s Esophagus. We have to accept that eradication of this infection is a two-edged sword that is both useful and harmful and we should therefore focus our H. pylori eradication policy toward selectively identify and destroy only the virulent strains.

Conclusion: In order to still be able to effectively treat H. pylori infections in the future we need an alternative diagnostic/treatment algorithm. This would involve a shift towards more precise and enhanced disease predicting diagnosis that tries to identify patients with chance of developing severe diseases such as gastric cancer, rather than the current regime that is geared towards find and destroy all H. pylori.

Keywords: H. pylori, Eradication therapy, Gastric cancer, Antimicrobial resistance

Background

With >50 % of the world’s population colonized by Helicobacter pylori it is one of the most prevalent human pathogens [1]. Infection with H. pylori is associated with chronic gastritis, duodenal ulcer, gastric cancer and even gastric adenocarcinoma [2]. Infection is usually acquired in childhood via person-to-person fecal-oral, oral-oral, or gastro-oral transmission being the most likely route of infection [3]. When ingested the bacterium colonizes the mucus layer covering the epithelial cells of the stomach and this induces an immune response that in spite of its vigor is unable to eliminate the bacterium [4]. The chronic infection that results from this vigorous but typically inadequate immune response induces gastric damage that is associated with digestive disorders ranging from chronic gastritis to peptic ulcer disease, and gastric cancer, but in most cases H. pylori infected patients remain asymptomatic for a long time [5]. In contrast to many other infectious agents the final outcome of a H. pylori infection is different for each infection and is dependent on both host and bacterial factors [1]. The large genetic variation observed among clinical strains of H. pylori is thought to be an important determinant in the specific local establishment of this colonization and determines in large part the development of the potential disorders that result from the infection [6]. The remarkable genetic and phenotypic diversity observed in H. pylori is thought to be driven by the need to adapt to the harsh and patient specific conditions of the gastric environment that often result in the genesis of various subpopulations (quasispecies) within single patients [7]. This results in each infected person potentially carrying genetically unique microorganisms existing only in that particular patient [7, 8]. Depending on the presence of specific H. pylori virulence factors such as dupA, cagA, vacA and homB the bacterium usually colonizes the antral mucosa of
human stomach [8]. Once this primary colonization is established it induces an inflammation that remains largely asymptomatic (Fig. 1) [9, 10]. In fact, an acute infection and subsequent gastritis precede the more severe digestive disorders such as gastric bleeding, peptic ulcers, and gastric cancer known to be associated with H. pylori infection (Fig. 1) [10]. While a long list of antibiotics has been tested for their effectiveness on H. pylori only a handful of them can be used for effective H. pylori eradication. Treatment options are further reduced as effective therapeutic regimen requires a combination of two or three antibiotics and a gastric acid suppressive drug [11]. Finally, in H. pylori antibiotic resistance to these drugs rapidly emerges as the resistance against all these drugs does not require the introduction of specific genes, but in all cases is based on a single point mutation in an existing housekeeping gene thus and obviously this further reduces a broad clinical efficacy significantly [4, 12, 13]. In parallel with emergence of multidrug resistant bacteria in other bacterial species, we need to accept that there is a rapid and ongoing reduction of the effective lifespan of antibiotics for clinical applications [14]. This has resulted in a situation where the big companies stopped or reduced their efforts to develop new antibiotics. While vaccination may be a practical approach for many pathogens, in the case of H. pylori vaccines do not seem to represent a viable option as sterilizing immunity is not considered an endpoint for now [15, 16]. As currently vaccines and pre/probiotics do not offer realistic H. pylori eradication strategies antibiotic treatment is currently the only available option to effectively reduce the gastrointestinal disorders resulting from H. pylori infection [17–19]. For now the further increase of antimicrobial resistance in H. pylori is being endangered by clinicians that frequently prescribe clarithromycin for patients suffering from upper respiratory diseases. Especially in developing countries many of these respiratory disease patients will also be colonized with H. pylori, but as here H. pylori infection is still in its early stage it will probably not have resulted in any significant disease symptoms and thus go unnoticed. Treating these patients with antibiotics with what should be considered for H. pylori as low dose, relative short period, and in the absence of an acid suppressive agent will not eradicate the H. pylori colonization but instead is very likely to promote the generation of resistant H. pylori. Hence we would need to create the awareness amongst clinicians that they might need to save the few remaining effective H. pylori drugs such as clarithromycin and amoxicillin and not use them freely for the treatment of common respiratory and urinary tract infections because of the consequences this may have on future H. pylori treatment of their patients. Or in minimum test for the absence of H. pylori in these patients and refrain from the use of effective H. pylori drugs when a patient is positive.

**Discussion**

While many diagnostic tests for detecting H. pylori are expensive and/or time consuming, our above suggestion to apply molecular detection will probably not get much support. Especially since currently when treating H. pylori infections more and more eradication therapies are being prescribed without testing for antimicrobial sensitivity in

---

**Fig. 1** Stopping the Helicobacter pylori induced disease cascade. Depending on the host and bacterial characteristics the initial colonization will result in gastritis and this will either result in clinical symptoms (symptomatic patient) where screening for the presence of Helicobacter and its resistance needs to be performed in order to allow for rational treatment. If the infection does not result in clinical symptoms (asymptomatic patient) it may still be advisable to use a single non-invasive fecal antigen screen at age 40 or so (when usually symptoms have not yet developed) to test for the presence of Helicobacter. When this test is positive fecal DNA test detecting Helicobacter specific virulence factors to predict infection with a virulent strain, and/or a noninvasive serologic follow-up screen to establish the degree of atrophy is advisable. If either of these tests predict there is a high risk for the development of gastric cancer eradication is advisable. Elimination of strains that contain virulence markers associated with an increased risk for disease development (regardless of what pathogenicity - if any it is causing in its current host) will reduce the spread of virulent strains and thereby force the population of circulating Helicobacter isolates into less pathogenic Helicobacters, irrespective of the contribution of host genetics and environmental factors.
order to save costs [17]. Effectively this means that often a combination therapy is prescribed without proper sensitivity testing. Due to increased resistance rates this may in fact effectively boil down to prescribing monotherapy. We know that in those cases treatment will not only be less effective, but in fact favors the generation of resistance to the one drug that was effective. While currently invasive procedures are still required in order to obtain material for culture and antimicrobial resistance determination, there is a now molecular method being developed that may allow for fecal matter based PCR testing for resistance against many of the commonly used H. pylori drugs [20, 21]. It will be relatively easy to also include a selection of H. pylori virulence markers in these tests, facilitating screening algorithm that would allow discriminating the good H. pylori from the bad. This would give rise to the screening and eradication scheme outlined in Fig. 1, where in principle only symptomatic patients would be treated after testing for virulence and resistance. Only anti-H. pylori therapies that can achieve eradication rate ≥90 % are considered effective, but increasing resistance hampers the efficacy of prescribed regimens [12, 21, 22]. Up to now we have taught clinicians to eradicate all cases of H. pylori infections as they would with any other pathogenic bacterial infection [23, 24]. However in the light of our current knowledge where only a minority of H. pylori infections will cause clinical symptoms screening for H. pylori and subsequent eradication may no longer be the best approach. For one, recent studies showed that asthma and other diseases can appear in the absence of H. pylori, an interesting phenomenon which complicates links between H. pylori infection and human disease [25, 26]. However we should consider occurrence of gastric cancer while it can be reduced in H. pylori infected patients through the elimination of H. pylori (either by antibiotic therapy or vaccine) [27, 28]. Current findings are indicate an association between H. pylori free individuals and certain immune dysfunctional diseases including allergy and asthma [26, 29], inflammatory bowel diseases (IBS) [30, 31] and Barrett’s Esophagus (BE) [32] in Helicobacter free patients. One has to be aware however that this protective link between H. pylori infections and immune related disorders is not always observed and thus disputed by some authors [33]. While infection with H. pylori will result in gastritis subsequently we should be aware that only very few infected patients, even when left untreated will actually develop gastric cancer. Basically, an Operative Link for Gastritis Assessment (OLGA)-staging system has been designed to simplify evaluation of gastric atrophy [34]. This staging system was an updated version of Sydney system, thus, the staging system can then rank the histologic phenotypes of gastritis with a progressively increasing gastric cancer risk [35]. Moreover, new challenge can be to develop different algorithms that would predict people with high risk of developing gastric cancer using the pathotype of the infecting strain of H. pylori. In this proposed algorithm, only virulent H. pylori strains should be targeted/eliminated, thus allowing non-virulent strains to remain in place and so that they can exert their beneficial effects. With Next Generation Sequencing (NGS) techniques slowly becoming a routine technique in human diagnostic laboratories and its prices and turn-around times rapidly falling finding and destroying only virulent H. pylori strains may soon become a viable option. The classical perception that all infections should be treated as potentially disease causing has promoted that clinicians were eager to eliminate H. pylori infections and that is why they used (or in our view perhaps massively overused) antibiotics to eradicate this infection.

Perhaps for the control of future symptoms in the currently asymptomatic H. pylori patients we should introduce a population based screen for the presence of H. pylori at age 50 using a non-invasive test like the fecal antigen test or urease breath tests to establish the presence of a H. pylori infection (Fig. 1) [36]. For those positive follow-up screening with either non-invasive molecular test that establishes the virulence of the infecting strain (see above), and/or a serologic tests that would predict the status of the atrophy [37]. If these tests would predict an increased risk of future disease development, treatment would then be indicated, and one would proceed as outlined above for the symptomatic patient. The problem of H. pylori antibiotic resistance is real and as a result, we are now confronted with a new generation of multi drug resistant H. pylori strains, for which suitable treatment options no longer exist.

**Conclusion**

Thus we may need to revise the available guidelines to include the option where the best possible treatment of an infection may no longer be geared towards blindly eradicating all infected patients (search and destroy) but be directed towards a selective eradication strategy (find and destroy only virulent strains). However this requires the implementation of effective strategies to identify virulent strains as well as awareness amongst physicians that treatment of all individual patients may severely limit the treatment options for our future patients.

**Abbreviations**

BE, Barrett’s esophagus; IBS, inflammatory bowel diseases; NGS, next generation sequencing; OLGA, operative link for gastritis assessment

**Acknowledgements**

None.
Funding
No funding was received for this study.

Availability of data and materials
This paper is an open access publication and all data are available in the public domain.

Authors’ contributions
A.T.B.A and J.G.K both made substantial contributions to conception and design, or acquisition of data, and analysis and interpretation of data and have been equally involved in the drafting of this manuscript and/or revising it critically for important intellectual content. Both authors gave approval of this final version of the manuscript.

Competing interests
All authors declare that they have no financial or non-financial competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Author details
1Medical Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. 2Department of Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands.

Received: 22 December 2015 Accepted: 21 July 2016
Published online: 12 August 2016

References
1. Bezmin Abadi ATI, Enzo, Yeong Yeh L. Why do we still have Helicobacter pylori in our stomachs? Malays J Med Sci. 2015;22(5):70–5.
2. Zhu Y, Zhou X, Wu J, Su J, Zhang G. Risk factors and prevalence of Helicobacter pylori infection in persistent high incidence area of gastric carcinoma in Yangzhong city. Gastroenterol Res Pract. 2014;2014:481365.
3. Gold BD. New approaches to Helicobacter pylori infection in children. Curr Gastroenterol Rep. 2001;3(3):235–47.
4. Talebi Bezmin Abadi A. Therapy of Helicobacter pylori: present medley and future prospective. Biomed Res Int. 2014;2014:124607.
5. Nicholson GL, Haier J. Role of chronic bacterial and viral infections in neurodegenerative, neurobehavioural/psychiatric, autoimmune and fatigue disorders: part 2. Br J Med Pract. 2010;3(1):301–10.
6. Yamaoka Y. Pathogenesis of Helicobacter pylori-related gastrointestinal diseases from molecular epidemiological studies. Gastroenterol Res Pract. 2012;2012:271503.
7. Farzi N, Malekian T, Alebouyeh M, Vaziri F, Zali MR. Genotype diversity and quasisspecies development of Helicobacter pylori in a single host. Jpn J Infect Dis. 2015;68(3):176–80.
8. Yamaoka Y, Graham DY. Helicobacter pylori virulence and cancer pathogenesis. Future Oncol. 2014;10(8):1487–500.
9. Portal-Celhay C, Perez-Perez GI. Immune responses to Helicobacter pylori colonization: mechanisms and clinical implications. Clin Sci. 2006;110(3):305–14.
10. Abadi ATB, Taghvaei T, Mobarez AM, Vaira G, Vaira D. High correlation of babA 2-positive strains of Helicobacter pylori with the presence of gastric cancer. Intern Emerg Med. 2013;8(6):497–501.
11. Sipponen P, Hyvärinen H. Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scand J Gastroenterol. 1993;28(suppl196):3–6.
12. Mégraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes. 2013;4(6):541–8.
13. Talebi Bezmin Abadi A. Updated Helicobacter pylori management in 2015. Saudi J Gastroenterol. 2016;22(1):80.
14. Mégraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes. 2013;4(6):541–8.
15. Fock KM, Graham DY, Malferttheiner P. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol. 2013;10(8):495–500.
16. Muller A, Solnick JV. Inflammation, immunity, and vaccine development for Helicobacter pylori. Helicobacter. 2011;16 Suppl 1:26–32.
17. Zhang S, Moise L, Mosk SF. H. pylori vaccines: why we still don’t have any. Human vaccines. 2011;7(11):1153–7.
18. Asakoa D, Nagahara A, Matsuhiha T, Takahashi S, Tokunaga K, Kawai T, Kawakami K, Suzuki H, Suzuki M, Nishizawa T. Trends of second line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area. Helicobacter. 2013;18(6):468–72.
19. Li W-Q, Ma J-L, Zhang L, Brown LM, Li J-Y, Shen L, Pan K-F, Liu W-D, Hu Y, Han Z-X. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst. 2014;106(7):djv116.
20. Abadi A, Bonten MJ, Kusters JG. Comment to “different antibiotic No culture eradication (DANCE) of Helicobacter pylori: an easy way to manage H. Pylori eradication”?. Dig Liver Dis. 2013;45(5):438–8.
21. Mégraud F, Bénéjat L, Ngoi ENO, Leheours P. Molecular approaches to identify Helicobacter pylori antimicrobial resistance. Gastroenterol Clin N Am. 2015;44(3):577–96.
22. Abadi ATB, Taghvaei T, Mobarez AM, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J Microbiol. 2011;49(6):987–93.
23. McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, Kelman A, Penny C, Knill-Jones R, Hilditch T. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 1998;339(26):1869–74.
24. Forbes G, Glaser M, Cullen D, Collins B, Warren J, Christensen K, Marshall B. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet. 1994;343(8892):258–60.
25. McCune A, Lane A, Murray L, Harvey L, Nair P, Donovan J, Harvey R. Reduced risk of atopic disorders in adults with Helicobacter pylori infection: Eur J Gastroenterol Hepatol. 2003;15(6):637–40.
26. Chen Y, Blaser MJ. Inverse associations of Helicobacter pylori with asthma and allergy. Arch Intern Med. 2007;167(8):821–7.
27. The ESG. An international association between Helicobacter pylori infection and gastric cancer. Lancet. 1993;341(8857):1359–63.
28. Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, Liu WD, Hu Y, Han ZX, Crystal-Mansour S, et al. Fifteen-year effects of Helicobacter pylori, gastric, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104(6):488–92.
29. Blaser MJ, Chen Y, Reibman J. Does Helicobacter pylori protect against asthma and allergy? Gut. 2008;57(5):561–7.
30. Rokkas T, Gilbert JP, Niv Y, O’Morain C. The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis. J Eur Gastroenterol J. 2015;36(5):539–50.
31. Luther J, Dave M, Higgins PD, Kao JY. Association between Helicobacter pylori infection and inflammatory bowel disease: a meta-analysis and systematic review of the literature. Inflamm Bowel Dis. 2010;16(6):1077–84.
32. Vaee MF, Falk GW, Peek RM, Viciu JJ, Goldblum JR, Perez-Perez GI, Rice TW, Blaser MJ, Richter JE. CagA-positive strains of Helicobacter pylori may protect against Barrett’s esophagus. Am J Gastroenterol. 2000;95(9):2206–11.
33. Wang Y, Bi Y, Zhang L, Wang C. Is Helicobacter pylori infection associated with asthma risk? a meta-analysis based on 770 cases and 785 controls. Int J Med Sci. 2012;9(7):603–10.
34. Rugge M, Genta RM. Staging gastritis: an international proposal. Gastroenterology. 2005;129(5):1907–8.
35. Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K, Genta RM, Graham DY, Hattori T, Malfertheiner P, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008;40(8):650–8.
36. Garza-Gonzalez E, Perez-Perez GI, Maldonado-Garza HJ, Bosques-Padilla FJ. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol. 2014;20(50):1438–49.
37. Syljänen KJ, Sipponen P, Härkönen M, Peetsalu A, Korpela S. Accuracy of the GastroPanel test in the detection of atrophic gastritis. Eur J Gastroenterol Hepatol. 2015;27(1):102.